Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 31 analyst ratings
Buy
Strong Buy 39%
Buy 55%
Hold 3%
Sell 3%
Strong Sell 0%

Bulls say

Insmed Inc is positioned for significant growth due to a robust pipeline of treatments addressing serious and rare diseases, with a particularly promising outlook for its lead product, ARIKAYCE, projected to generate global revenues of $405M to $425M by 2025. The anticipated launch of Brensocatib in 2025 is expected to be highly successful, potentially reaching peak sales of $8.2B, driven by strong demand from both patients and physicians in a market with limited alternative treatments. Additionally, Insmed's recent expansion of its commercial infrastructure, including an increase in sales representatives and strategic market access initiatives, further enhances its operational capabilities to capitalize on upcoming launches and pipeline potential.

Bears say

Insmed Inc faces significant challenges that contribute to a negative outlook for its stock, primarily due to risks associated with its clinical pipeline, including potential safety issues, regulatory hurdles, and efficacy concerns that could impede the progress of its drug candidates. The company reported substantial net losses of $235.5 million for the fourth quarter of FY24 and $913.8 million for the fiscal year, raising concerns about its financial viability if its products fail to generate sufficient revenue. Given the ongoing financial pressures coupled with high research and development expenditures, there is a risk that Insmed may struggle to finance its operations, especially if its commercial ventures do not succeed.

Insmed (INSM) has been analyzed by 31 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 55% recommend Buy, 3% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 31 analysts, Insmed (INSM) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.84, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.84, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.